Microbiota, Probiotic and Dietary Metabolite Control of Enteric Pathogen Virulence

项目总结 来自微生物区系、益生菌和饮食的关键代谢物可以抑制肠道病原体的毒力特性， 但它们的作用机制尚不清楚，限制了新抗感染药物的开发。要确定 主要微生物区系代谢物(短链脂肪酸、芳香氨基酸、胆汁)的作用机理(S) 酸和其他)，需要多学科的方法来生化识别代谢物-蛋白质靶标 在肠道病原体中，并表征其对体内感染的活性。因此，我的实验室将雇用 在化学生物学、蛋白质组学和细菌基因编辑方面的创新方法，以阐明其特异性 代谢产物可减轻肠道病原体感染。更好地了解这些代谢物是如何影响 细菌病原体的毒力特性应该揭示潜在的治疗靶点，并促进 开发新的抗感染药物以对抗动物和人类的细菌病原体。

PROJECT SUMMARY Key metabolites from microbiota, probiotics and diet can inhibit the virulence properties of enteric pathogens, but their mechanisms of action are unclear and limit the development of new anti-infectives. To determine the mechanism(s) of action of prominent microbiota metabolites (short chain fatty acids, aromatic amino acids, bile acids and others), multi-disciplinary approaches are needed to biochemically identify metabolite-protein targets in enteric pathogens and characterize their activity on infections in vivo. My laboratory will therefore employ innovative methods in chemical biology, proteomics and gene editing in bacteria to elucidate how specific metabolites attenuates enteric pathogen infections. A better understanding of how these metabolites affects the virulence properties of bacterial pathogens should reveal potential therapeutic targets and facilitate the development of new anti-infectives to combat bacterial pathogens in animals and humans.